Advertisement

The FDA gives Teleflex clearance to market more models of its Arrow GPSCath balloon dilatation device suite, which the company picked up during the 2012 Hotspur buyout.

Teleflex (NYSE:TFX) won FDA clearance for expanded sizes and uses of its Arrow GPSCath Balloon Dilatation catheter, a device the company picked up during the 2012 buyout of Hotspur Technologies.

The FDA win lets Teleflex sell the catheter in new 80 cm lengths and in a higher burst pressure rating. The Limerick, Pa.-based device company calls the Arrow GPS a "dual-function" balloon catheter because of its ability to widen arteries while injecting fluids.

Advertisement
Advertisement